Denali Therapeutics stock price rises as FDA freezes rival Regenxbio’s Hunter syndrome gene therapy trials
New York, Jan 29, 2026, 15:20 EST — Regular session • Denali Therapeutics shares climbed in afternoon trading, gaining ground while the broader biotech sector remained flat.• Attention intensified following the FDA’s decision to halt Regenxbio’s rare-disease gene therapy trials.• Investors are now zeroed in on Denali’s FDA timeline for its Hunter syndrome treatment and the data update expected in…